Recent progress in the development of steroid sulfatase inhibitors – examples of the novel and most promising compounds from the last decade - Publikacja - MOST Wiedzy

Wyszukiwarka

Recent progress in the development of steroid sulfatase inhibitors – examples of the novel and most promising compounds from the last decade

Abstrakt

The purpose of this review article is to provide an overview of recent achievements in the synthesis of novel steroid sulfatase (STS) inhibitors. STS is a crucial enzyme in the biosynthesis of active hormones (including estrogens and androgens) and, therefore, represents an extremely attractive molecular target for the development of hormone-dependent cancer therapies. The inhibition of STS may effectively reduce the availability of active hormones for cancer cells, causing a positive therapeutic effect. Herein, we report examples of novel STS inhibitors based on steroidal and nonsteroidal cores that contain various functional groups (e.g., sulfamate and phosphorus moieties) and halogen atoms, which may potentially be used in therapies for hormone-dependent cancers. The presented work also includes examples of multitargeting agents with STS inhibitory activities. Furthermore, the fundamental discoveries in the development of the most promising drug candidates exhibiting STS inhibitory activities are highlighted.

Cytowania

  • 5

    CrossRef

  • 3

    Web of Science

  • 5

    Scopus

Cytuj jako

Pełna treść

pobierz publikację
pobrano 21 razy
Wersja publikacji
Accepted albo Published Version
Licencja
Creative Commons: CC-BY otwiera się w nowej karcie

Słowa kluczowe

Informacje szczegółowe

Kategoria:
Publikacja w czasopiśmie
Typ:
artykuły w czasopismach
Opublikowano w:
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY nr 35, strony 1163 - 1184,
ISSN: 1475-6366
Język:
angielski
Rok wydania:
2020
Opis bibliograficzny:
Daśko M., Demkowicz S., Biernacki K., Ciupak O., Kozak W., Masłyk M., Rachoń J.: Recent progress in the development of steroid sulfatase inhibitors – examples of the novel and most promising compounds from the last decade// JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY -Vol. 35,iss. 1 (2020), s.1163-1184
DOI:
Cyfrowy identyfikator dokumentu elektronicznego (otwiera się w nowej karcie) 10.1080/14756366.2020.1758692
Bibliografia: test
  1. Lyon (France): International Agency for Research on Cancer [cited 2019 otwiera się w nowej karcie
  2. NCI: Cancer Statistics [Internet]. otwiera się w nowej karcie
  3. Bethesda (MD): National Cancer Institute [cited 2019 July 16]. Available from: https://www.cancer.gov/about-cancer/understanding/statistics.
  4. Pasqualini JR. The selective estrogen enzyme modulators in breast cancer: a review. Biochim Biophys Acta 2004; 1654: 123-43. otwiera się w nowej karcie
  5. Poirier D. Recent patents on new steroid agents targeting the steroidogenesis for endocrine cancer treatments. Recent Pat Endocr Metab Immune Drug Discov 2015;9: 15-23. otwiera się w nowej karcie
  6. Saha T, Makar S, Swetha R, et al. Estrogen signaling: an emanating therapeutic target for breast cancer treatment. Eur J Med Chem 2019;177:116-43. otwiera się w nowej karcie
  7. Shah R, Singh J, Singh D, et al. Sulfatase inhibitors for recidivist breast cancer treatment: a chemical review. Eur J Med Chem 2016;114:170-90. otwiera się w nowej karcie
  8. Foster PA, Chander SK, Newman SP, et al. A new thera- peutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfa- tase inhibitor. Clin Cancer Res 2008;14:6469-77. otwiera się w nowej karcie
  9. Dixon JM. Endocrine resistance in breast cancer. New J Sci 2014;2014:1-27. otwiera się w nowej karcie
  10. Reinert T, Saad ED, Barrios CH, et al. Clinical implications of ESR1 mutations in hormone receptor-positive advanced breast cancer. Front Oncol 2017;7:26. otwiera się w nowej karcie
  11. Augusto TV, Correia-da-Silva G, Rodrigues CMP, et al. Acquired resistance to aromatase inhibitors: where we stand. ! Endocr Relat Cancer 2018;25:R283-301. otwiera się w nowej karcie
  12. Mueller JW, Gilligan LC, Idkowiak J, et al. The regulation of steroid action by sulfation and desulfation. Endocr Rev 2015;36:526-63. otwiera się w nowej karcie
  13. Foster PA, Reed MJ, Purohit A. Recent developments of steroid sulfatase inhibitors as anti-cancer agents. Anti- Cancer Agents Med Chem 2008;8:732-8. otwiera się w nowej karcie
  14. Smith HJ, Simons C, Development of enzyme inhibitors as drugs. In: Smith HJ, Simons C, eds. Enzymes and their inhibition: drug development. London: CRC Press; 2005; 171-250.
  15. Reed MJ, Purohit A, Woo LWL, et al. Steroid sulfatase: molecular biology, regulation and inhibition. Endocr Rev 2005;26:171-202. otwiera się w nowej karcie
  16. Miki Y, Nakata T, Suzuki T, et al. Systemic distribution of steroid sulfatase and estrogen sulfotransferaze in human adult and fetal tissues. J Clin Endocrinol Metabol 2002;87: 5760-8. otwiera się w nowej karcie
  17. Hanson SR, Best MD, Wong CH. Sulfatases: structure, mech- anism, biological activity, inhibition, and synthetic utility. Angew Chem Ind Ed 2004;43:5736-63. otwiera się w nowej karcie
  18. Thomas MP, Potter B. The structure biology of estrogen metabolites. J Steroid Biochem Mol Biol 2013;137:27-49. otwiera się w nowej karcie
  19. Purohit A, Foster PA. Steroid sulfatase inhibitors for estro- gen-and androgen-dependent cancers. J Endocrinol 2012; 212:99-110. otwiera się w nowej karcie
  20. Hernandez-Guzman FG, Higashiyama T, Pangborn W, et al. Structure of human estrone sulfatase suggests functional roles of membrane association. J Biol Chem 2003;278: 22989-97. otwiera się w nowej karcie
  21. Ghosh D. Human sulfatases: a structural perspective to catalysis. Cell Mol Life Sci 2007;64:2013-22. otwiera się w nowej karcie
  22. Selmer T, Hallmann A, Schmidt B, et al. The evolutionary conservation of a novel protein modification, the conver- sion of cysteine o serine-semialdehyde in arylsulfatase from Volvox carteri. Eur J Biochem 1996;238:341-5. otwiera się w nowej karcie
  23. Maltais R, Poirier D. Steroid sulfatase inhibitors: a review covering the promising 2000-2010 decade. Steroids 2011; 76:929-48. otwiera się w nowej karcie
  24. Mostafa YA, Taylor SD. Steroid derivatives as inhibitors of steroid sulfatase. J Steroid Biochem Mol Biol 2013;137: 183-98. otwiera się w nowej karcie
  25. Woo LWL, Purohit A, Potter B. Development of steroid sul- fatase inhibitors. Mol Cell Endocrinol 2011;340:176-85. otwiera się w nowej karcie
  26. Geisler J, Sasano H, Chen S, et al. Steroid sulfatase inhibi- tors: promising new tools for breast cancer therapy? J Steroid Biochem Mol Biol 2011;125:39-45. otwiera się w nowej karcie
  27. Potter B, SULFATION P. Steroid sulphatase inhibition via aryl sulphamates: clinical progress, mechanism and future prospects. J Mol Endocrinol 2018;61:T233-52. otwiera się w nowej karcie
  28. Thomas MP, Potter B. Discovery and development of the aryl O-sulfamate pharmacophore for oncology and wom- en's health. J Med Chem 2015;58:7634-58. otwiera się w nowej karcie
  29. Rizner TL. The important roles of steroid sulfatase and sul- fotransferases in gynecological diseases. Front Pharmacol 2016;7:1-16. otwiera się w nowej karcie
  30. Sadozai H. Steroid sulfatase inhibitors: promising new ther- apy for breast cancer. J Pak Med Assoc 2013;63:509-15. otwiera się w nowej karcie
  31. Howarth NM, Cooper G, Purohit A, et al. Phosphonates and thiophosphonates as sulfate surrogates: synthesis of estrone-3-methylthiophosphonates, a potent inhibitor of estrone sulfatase. Bioorg Med Chem Lett 1993;3:313-8. otwiera się w nowej karcie
  32. Duncan L, Purohit A, Howarth NM, et al. Inhibition of estrone sulfatase activity by estrone-3-methylthiophospho- nate: a potential therapeutic agent in breast cancer. Cancer Res 1993;53:298-303.
  33. Howarth NM, Purohit A, Reed MJ, et al. Estrone sulfamates: potent inhibitors of estrone sulfatase with therapeutic potential. J Med Chem 1994;37:219-21. otwiera się w nowej karcie
  34. Purohit A, Williams GJ, Howarth NM, et al. Inactivation of sulfatase by an active site-directed inhibitor, estrone-3-O- sulfamate. Biochemistry 1995;34:11508-14. otwiera się w nowej karcie
  35. Elger W, Barth A, Hedden A, et al. Estrogen sulfamates: a new approach to oral estrogen therapy. Reprod Fertil Dev 2001;13:297-305. otwiera się w nowej karcie
  36. Hidalgo Aragones MI, Purohit A, Parish D, et al. Pharmacokinetics of oestrone-3-O-sulphamate. J Steroid Biochem Mol Biol 1996;58:611-7.
  37. Elger W, Schwarz S, Hedden A, et al. Sulfamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral application. J Steroid Biochem Mol Biol 1995;55:395-403. otwiera się w nowej karcie
  38. Pohl O, Bestel E, Gotteland JP. Synergistic effects of E2MATE and norethindrone acetate on steroid sulfatase inhibition: a randomized phase I proof-of-principle clinical study in women of reproductive age. Reprod Sci 2014;21: 1256-65. otwiera się w nowej karcie
  39. Colette S, Defr ere S, Lousse JC, et al. Inhibition of steroid sulfatase decreases endometriosis in an in vivo murine model. Hum Reprod 2011;26:1362-70. otwiera się w nowej karcie
  40. Woo LWL, Leblond B, Purohit A, et al. Synthesis and evalu- ation of analogues of estrone-3-O-sulfamate as potent ster- oid sulfatase inhibitors. Bioorg Med Chem 2012;20: 2506-19.
  41. Mostafa YA, Taylor SD. 17b-arylsulfonamides of 17b-amino- estra-1,3,5(10)-trien-3-ol as highly potent inhibitors of ster- oid sulfatase. Bioorg Med Chem 2012;20:1535-44. otwiera się w nowej karcie
  42. Mostafa YA, Kralt B, Rao PPN, et al. A-ring substituted 17b- arylsulfonamides of 17b-aminoestra-1,3,4,(10)-trien-3-ol as highly potent reversible inhibitors of steroid sulfatase. Bioorg Med Chem 2015;23:5681-92. otwiera się w nowej karcie
  43. Grienke U, Kaserer T, Kirchweger B, et al. Steroid sulfatase inhibiting lanostane triterpenes -Structure activity relation- ship and in silico insights. Bioorg Chem 2020;95:103495. otwiera się w nowej karcie
  44. Maltais R, Djiemeny AN, Roy J, et al. Design and synthesis of dansyl-labeled inhibitors of steroid sulfatase for optical imaging. Bioorg Med Chem 2020;28:115368. otwiera się w nowej karcie
  45. Fournier D, Poirier D. Chemical synthesis and evaluation of 17alpha-alkylated derivatives of estradiol as inhibitors of steroid sulfatase. Eur J Med Chem 2011;46:4227-37. otwiera się w nowej karcie
  46. Boivin RP, Luu-The V, Lachance R, et al. Structure-activity relationships of 17alpha-derivatives of estradiol as inhibi- tors of steroid sulfatase. J Med Chem 2000;43:4465-78. otwiera się w nowej karcie
  47. Purohit A, Woo LWL, Singh A, et al. In vivo activity of 4- methylcoumarin-7-O-sulfamate, a nonsteroidal, nonestro- genic steroid sulfatase inhibitor. Canc Res 1996;56:4950-5.
  48. Woo LWL, Howarth NM, Purohit A, et al. Steroidal and non- steroidal sulfamates as potent inhibitors of steroid sulfa- tase. J Med Chem 1998;41:1068-83. otwiera się w nowej karcie
  49. Malini B, Purohit A, Ganeshapillai D, et al. Inhibition of ster- oid sulphatase activity by tricyclic coumarin sulphamates. J Steroid Biochem Mol Biol 2000;75:253-8. otwiera się w nowej karcie
  50. Woo LWL, Purohit A, Malini B, et al. Potent active site- directed inhibition of steroid sulphatase by tricyclic couma- rin-based sulphamates. Chem Biol 2000;7:773-91. otwiera się w nowej karcie
  51. Woo LWL, Ganeshapillai D, Thomas MP, et al. Structure- activity relationship for the first-in-class clinical steroid sul- fatase inhibitor Irosustat (STX64, BN83495). Chem Med Chem 2011;6:2019-34. otwiera się w nowej karcie
  52. Parra-Guillen ZP, Cendr os Carreras JM, Peraire C, et al. Population pharmacokinetic modelling of Irosustat in post- menopausal women with Oestrogen-receptor positive breast cancer incorporating non-linear red blood cell uptake. Pharm Res 2015;32:1493-504. otwiera się w nowej karcie
  53. Coombes RC, Cardoso F, Nicolas I, et al. A phase I dose escalation study to determine the optimal biological dose of irosustat, an oral steroid sulfatase inhibitor, in postme- nopausal women with estrogen receptor-positive breast cancer. Breast Cancer Res Treat 2013;140:73-82. otwiera się w nowej karcie
  54. Stanway SJ, Purohit A, Woo LWL, et al. Phase I study of STX64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. Clin Cancer Res 2006; 12:1585-92. otwiera się w nowej karcie
  55. Palmieri C, Januszewski A, Stanway S, et al. Irosustat: a first-generation steroid sulfatase inhibitor in breast cancer. Expert Rev Anticancer Ther 2011;11:179-83. otwiera się w nowej karcie
  56. Palmieri C, Stein RC, Liu X, et al. IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients. Breast Cancer Res Treat 2017;165:343-53. otwiera się w nowej karcie
  57. Palmieri C, Stein RC, Liu X, et al. A phase II study to assess the safety and efficacy of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER posi- tive locally advanced or metastatic breast cancer patient (IRIS) -trial results. J Clin Oncol 2016;34:549. otwiera się w nowej karcie
  58. Palmieri C, Szydlo R, Miller M, et al. IPET study: an FLT-PET window study to assess the activity of the steroid sulfatase inhibitor irosustat in early breast cancer. Breast Cancer Res Treat 2017;166:527-39. otwiera się w nowej karcie
  59. Pautier P, Vergote I, Joly F, et al. A phase 2, randomized, open-label study of Irosustat versus megestrol acetate in advanced endometrial cancer. Int J Gynecol Cancer 2017; 27:258-66. otwiera się w nowej karcie
  60. Ganeshapillai D, Woo LWL, Thomas MP, et al. C-3-and C-4- substituted bicyclic coumarin sulfamates as potent steroid sulfatase inhibitors. ACS Omega 2018;3:10748-72. otwiera się w nowej karcie
  61. Hng Y, Lin MH, Lin TS, et al. Design and synthesis of 3-ben- zylaminocoumarin-7-O-sulfamate derivatives as steroid sul- fatase inhibitors. Bioorg Chem 2020;96:103618. otwiera się w nowej karcie
  62. Demkowicz S, Da sko M, Kozak W, et al. Synthesis and bio- logical evaluation of fluorinated 3-phenylcoumarin-7-O- sulfamate derivative as steroid sulfatase inhibitors. Chem Biol Drug Des 2016;87:233-8. otwiera się w nowej karcie
  63. Da sko M, Przybyłowska M, Rachon J, et al. Synthesis and biological evaluation of fluorinated N-benzoyl and N-phe- nylacetoyl derivatives of 3-(4-aminophenyl)-coumarin-7-O- sulfamate as steroid sulfatase inhibitors. Eur J Med Chem 2017;128:79-87.
  64. Da sko M, Rachon J, Masłyk M, et al. Synthesis and bio- logical evaluation of N-acylated tyramine sulfamates con- taining C-F bonds as steroid sulfatase inhibitors. Chem Biol Drug Des 2017; 90:156-61.
  65. Da sko M, Demkowicz S, Rachon J, et al. New potent STS inhibitors based on fluorinated 4-(1-phenyl-1H-[1,2,3]tria- zol-4-yl)-phenyl sulfamates. J Asian Nat Prod Res 2019. doi: 10.1080/10286020.2019.1680642. otwiera się w nowej karcie
  66. Kajita D, Nakamura M, Matsumoto Y, et al. Design and syn- thesis of silicon-containing steroid sulfatase inhibitors pos- sessing pro-estrogen antagonistic character. Bioorg Med Chem 2014;22:2244-52. otwiera się w nowej karcie
  67. El-Gamal MI, Semreen MH, Foster PA, et al. Design, synthe- sis, and biological evaluation of new arylamide derivatives possessing sulfonate or sulfamate moieties as steroid sulfa- tase enzyme inhibitors. Bioorg Med Chem 2016;24:2762-7. otwiera się w nowej karcie
  68. Moi D, Foster PA, Rimmer LG, et al. Synthesis and in vitro evaluation of piperazinyl-ureido sulfamates as steroid sulfa- tase inhibitors. Eur J Med Chem 2019;182:111614. otwiera się w nowej karcie
  69. Zhou Y, Wang J, Gu Z, et al. Next generation of fluorine- containing pharmaceuticals, compounds currently in phase II-III clinical trials of major pharmaceutical companies: new structural trends and therapeutic areas. Chem Rev 2016; 116:422-518. otwiera się w nowej karcie
  70. Kitchen DB, Decornez H, Furr JR, et al. Docking and scoring in virtual screening for drug discovery: methods and appli- cations. Nat Rev Drug Discov 2004;3:935-49. otwiera się w nowej karcie
  71. Jagiello K, Sosnowska A, Kar S, et al. Geometry optimiza- tion of steroid sulfatase inhibitors -the influence on the free binding energy with STS. Struct Chem 2017;28: 1017-32. otwiera się w nowej karcie
  72. Yue XH, Tong JQ, Wang ZJ, et al. Steroid sulfatase inhibitor DU-14 protects spatial memory and synaptic plasticity from disruption by amyloid b protein in male rats. Horm Behav 2016;83:83-92. otwiera się w nowej karcie
  73. Li PK, Milano S, Kluth L, et al. Synthesis and sulfatase inhibitory activities of non-steroidal estrone sulfatase inhib- itors. J Steroid Biochem Mol Biol 1996;59:41-48. otwiera się w nowej karcie
  74. Selcer KW, Hegde PV, Li PK. Inhibition of estrone sulfatase and proliferation of human breast cancer cells by nonster- oidal (p-O-sulfamoyl)-N-alkanoyl tyramines. Cancer Res 1997;57:702-7.
  75. Li PK, Rhodes ME, Burke AM, et al. Memory enhancement mediated by the steroid sulfatase inhibitor (p-O-sulfamoyl)- N-tetradecanoyl tyramine. Life Sci 1997;60:45-51. otwiera się w nowej karcie
  76. Demkowicz S, Rachon J, Da sko M, et al. Selected organo- phosphorus compounds with biological activity. Applications in medicine. RSC Adv 2016;6:7101-7112. otwiera się w nowej karcie
  77. Kozak W, Rachon J, Da sko M, et al. Selected methods for the chemical phosphorylation and thiophosphorylation of phenols. Asian J Org Chem 2018;7:314-23. otwiera się w nowej karcie
  78. Demkowicz S, Kozak W, Da sko M, et al. Phosphoroorganic metal complexes in therapeutics. Mini Rev Med Chem 2016;16:1359-73. otwiera się w nowej karcie
  79. Kozak W, Da sko M, Masłyk M, et al. Phosphate tricyclic cou- marin analogs as steroid sulfatase inhibitors: synthesis and biological activity. RSC Adv 2014;4:44350-8. otwiera się w nowej karcie
  80. Kozak W, Da sko M, Masłyk M, et al. Synthesis and bio- logical evaluation of thiophosphate tricyclic coumarin derivatives as steroid sulfatase inhibitors. J Asian Nat Prod Res 2015;17:1091-6. otwiera się w nowej karcie
  81. Demkowicz S, Kozak W, Da sko M, et al. Synthesis of bicou- marin thiopshosphate derivatives as steroid sulfatase inhib- itors. Eur J Med Chem 2015;101:358-66. otwiera się w nowej karcie
  82. Demkowicz S, Kozak W, Da sko M, et al. Phosphate and thi- ophosphate biphenyl analogs as steroid sulfatase inhibi- tors. Drug Dev Res 2015;76:94-104. otwiera się w nowej karcie
  83. Kozak W, Da sko M, Masłyk M, et al. Steroid sulfatase inhibi- tors based on phosphate and thiophosphate flavone ana- logs. Drug Dev Res 2015;76:450-62. otwiera się w nowej karcie
  84. Kozak W, Da sko M, Wołos A, et al. Synthesis and steroid sulfatase inhibitory activities of N-alkanoyl tyramine phos- phates and thiophosphates. RSC Adv 2015;5:32594-603. otwiera się w nowej karcie
  85. Da sko M, Masłyk M, Kubi nski K, et al. Synthesis and steroid sulfatase inhibitory activities of N-phosphorylated 3-(4-ami- nophenyl)-coumarin-7-O-sulfamates. Med Chem Commun 2016;7:1146-50.
  86. Da sko M, Demkowicz S, Biernacki K, et al. Novel steroid sul- fatase inhibitors based on N-thiophosphorylated 3-(4-ami- nophenyl)-coumarin-7-O-sulfamates. Drug Dev Res 2019;80: 857-866.
  87. Woo LWL, Sutcliffe OB, Bubert C, et al. First dual aroma- tase-steroid sulfatase inhibitors. J Med Chem 2003;46: 3193-6. otwiera się w nowej karcie
  88. Woo LWL, Jackson T, Putey A, et al. Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on biphenyl template. J Med Chem 2010;53: 2155-70. otwiera się w nowej karcie
  89. Woo LWL, Bubert C, Purohit A, et al. Hybrid dual aroma- tase-steroid sulfatase inhibitors with exquisite picomolar inhibitory activity. ACS Med Chem Lett 2011;2:243-7. otwiera się w nowej karcie
  90. Woo L, Wood PM, Bubert C, et al. Synthesis and structure- activity relationship studies of derivatives of the dual aro- matase-sulfatase inhibitor 4-f[(4-cyanophenyl)(4H-1,2,4-tria- zol-4-yl)amino]methylgphenyl sulfamate. ChemMedChem 2013;8:779-99. otwiera się w nowej karcie
  91. Wood PM, Woo LWL, Labrosse JR, et al. Chiral aromatase and dual aromatase-steroid sulfatase inhibitors from the letrozole template: synthesis, absolute configuration, and in vitro activity. J Med Chem 2008;51:4226-38. otwiera się w nowej karcie
  92. Jackson T, Woo LWL, Trusselle MN, et al. Dual aromatase- sulfatase inhibitors based on the anastrozole template: syn- thesis, in vitro SAR, molecular modeling and in vivo activity. Org Biomol Chem 2007;5:2940-52. otwiera się w nowej karcie
  93. Salah M, Abdelsamie AS, Frotscher M. First dual inhibitors of steroid sulfatase (STS) and 17b-hydroxysteroid dehydro- genase type 1 (17b-HSD1): designed multiple ligands as novel potential therapeutics for estrogen-dependent dis- eases. J Med Chem 2017;60:4086-92. otwiera się w nowej karcie
  94. Bacsa I, Herman BE, J oj art R, et al. Synthesis and structure- activity relationships of 2-and/or 4-genated 13b-and 13a- estrone derivatives as enzyme inhibitors of estrogen bio- synthesis. J Enzyme Inhib Med Chem 2018;33:1271-82. otwiera się w nowej karcie
  95. Potter BVL, Reed LWL, Woo LWL, et al. Sulfamic acid ester compounds useful in the inhibition of steroid sulphatase activity and aromatase activity. US patent 20070213383; 2007.
  96. Woo LWL, Bubert C, Sutcliffe OB, et al. Dual aromatase-ster- oid sulfatase inhibitors. J Med Chem 2007;50:3540-60. otwiera się w nowej karcie
  97. Wood PM, Woo LWL, Labrosse JR, et al. Bicyclic derivatives of the potent dual aromatase-steroid sulfatase inhibitor 2- bromo-4-f[(4-cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]me- thylgphenylsulfamate: synthesis, SAR, crystal structure, and in vitro and in vivo activities. ChemMedChem 2010;5: 1577-93. otwiera się w nowej karcie
  98. Wood PM, Woo LWL, Thomas MP, et al. Aromatase and dual aromatase-steroid sulfatase inhibitors from the Letrozole and Vorozole templates. ChemMedChem 2011;6: 1423-38. otwiera się w nowej karcie
  99. Lafay J, Rondot B, Bonnet P, et al. 1-N-phenyl-amino-1h- imidazole derivatives and pharmaceutical compositions containing them. US patent 20070112009; 2007. otwiera się w nowej karcie
  100. Woo LWL, Jackson T, Bubert C, et al. Phenyl-sulfamates as aromatase inhibitors. US patent 7763642; 2010.
  101. Potter BVL, Reed MJ, Woo LWL, et al. Oestrogen-17-supha- mates as inhibitors of steroid sulphatase. US Patent 8030296; 1996.
  102. Tagg SLC, Foster PA, Leese MP, et al. 2-Methoxyestradiol- 3,17-O,O-bis-sulphamate and 2-deoxy-D-glucose in combination: a potential treatment for breast and prostate cancer. Br J Cancer 2008;99:1842-48. otwiera się w nowej karcie
  103. Raobaikady B, Purohit A, Chander SK, et al. Inhibition of MCF-7 breast cancer cell proliferation and in vivo steroid sulphatase activity by 2-methoxyoestradiol-bis-sulphamate. J Steroid Biochem Mol Biol 2003;84:351-8. otwiera się w nowej karcie
  104. Leese MP, Leblond B, Smith A, et al. 2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis in vitro SAR, protein crystallography, and in vivo activity. J Med Chem 2006;49:7683-96. otwiera się w nowej karcie
  105. Utsumi T, Leese MP, Chander SK, et al. The effects of 2- methoxyestrogen sulphamates on the in vitro and in vivo proliferation of breast cancer cells. J Steroid Biochem Mol Biol 2005;94:219-27. otwiera się w nowej karcie
  106. Ireson CR, Chander SK, Purohit A, et al. Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestra- diol-bis-sulphamate in vivo in rodents. Br J Cancer 2004;90: 932-7. otwiera się w nowej karcie
  107. Thomas MP, Potter B. Estrogen O-sulfamates and their ana- logues: clinical steroid sulfatase inhibitors with broad potential. J Steroid Biochem Mol Biol 2015;153:160-9. otwiera się w nowej karcie
  108. Newman SP, Foster PA, Stengel C, et al. STX140 is effica- cious in vitro and in vivo in taxane-resistant breast carcin- oma cells. Clin Cancer Res 2008;14:597-606. otwiera się w nowej karcie
  109. Meyer-Losic F, Newman SP, Day JM, et al. STX140, but not Paclitaxel, inhibits mammary tumor initiation and progres- sion in C3(1)/SV40T/t-antigen transgenic mice. PLoS One 2013;8:e80305. otwiera się w nowej karcie
  110. Wang M, Xu L, Mingzhang G, et al. Synthesis of 2- [ 11 C]methoxy-3,17b-O,O-bis(sulfamoyl)estradiol as a new potential PET agent for imaging of steroid sulfatase (STS) in cancers. Steroids 2012;77:864-70. otwiera się w nowej karcie
  111. Jourdan F, Leese MP, Dohle W, et al. Synthesis, antitubulin and antiproliferative SAR of analogues of 2-methoxyestra- diol-3,17-O,O-bis sulfamate. J Med Chem 2010;53:2942-51. otwiera się w nowej karcie
  112. Jourdan F, Leese MP, Dohle W, et al. Structure-activity rela- tionships of C-17-substituted estratriene-3-O-sulfamates as anticancer agents. J Med Chem 2011;54:4863-79. otwiera się w nowej karcie
  113. Potter BVL, Reed MJ, Lebrond B, et al. Aryl linker deriva- tised estrogen 3-sulfamates as inhibitors of steroid sulfa- tase. US patent 7067503; 2006.
  114. Poirier D, Roy J, Maltais R, et al. A potent inhibitor of ster- oid sulfatase (EM-1913) blocks tumor growth in nude mice (MCF-7 xenograft). Curr Enzyme Inhib 2015;11:65-73. otwiera się w nowej karcie
  115. Ouellet E, Maltais R, Ouellet C, et al. Investigation of a tet- rahydroisoquinoline scaffold as dual-action steroid sulfatase inhibitors generated by parallel solid phase synthesis. Med Chem Commun 2013;4:681-92. otwiera się w nowej karcie
  116. Ouellet C, Ouellet E, Poirier D. In vitro evaluation of a tetra- hydroisoquinoline derivative as a steroid sulfatase inhibitor and a selective estrogen receptor modulator. Invest New Drugs 2015;33:95-103. otwiera się w nowej karcie
  117. Ouellet C, Maltais R, Ouellet E, et al. Discovery of a sulfa- mate-based steroid sulfatase inhibitor with intrinsic select- ive estrogen receptor modulator properties. Eur J Med Chem 2016;119:169-82. otwiera się w nowej karcie
  118. Poirier D, Roy J, Maltais R, et al. Antisulfatase, osteogenic, and anticancer activities of steroid sulfatase inhibitor EO-33 in mice. J Med Chem 2019;62:5512-21. otwiera się w nowej karcie
  119. Kaise A, Ohta K, Endo Y. Novel p-carborane-containing mul- titarget anticancer agents inspired by the metabolism of 17b-estradiol. Bioorg Med Chem 2017;25:6371-78. otwiera się w nowej karcie
  120. Kaise A, Ohta K, Shirata C, et al. Design and synthesis of p- carborane-containing sulfamates as multitarget anti-breast cancer agents. Bioorg Med Chem 2017;25:6417-26. otwiera się w nowej karcie
Źródła finansowania:
Weryfikacja:
Politechnika Gdańska

wyświetlono 62 razy

Publikacje, które mogą cię zainteresować

Meta Tagi